Clinical Trial Update: Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease [Phase 2]

View source ↗

Summary

A multicenter Phase 2 trial is underway to evaluate Seliciclib (R-roscovitine) for Cushing disease and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Disease

Drugs mentioned

• Seliciclib (R-roscovitine) (seliciclib)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Cushing Disease | Phase 2 | Status: RECRUITING